Figure 2.

N-Glycosylation as a target for cancer immunotherapy. Remodeling of the immune-suppressive microenvironment can be achieved by targeting receptor N-glycosylation by blocking the catalytic pathway with enzyme inhibitors or developing glycan-specific antibodies.